Pharma BD Deal Intelligence
FierceBiotech framed the deal as J&J 'snagging another promising prostate cancer drug' that complements blockbuster Zytiga, with Janssen oncology head Peter…
Zacks noted J&J shares ticked up ~0.85% on the announcement while Medivation shares fell ~6.78%, signaling investor expectation that ARN-509 could meaningfully…
FirstWord characterized ARN-509 as J&J's 'billion-dollar prostate cancer bet' and surfaced the late-stage development path designed to leverage Zytiga's…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
J&J to acquire Aragon for $650M upfront + up to $350M milestones ($1B total); pre-close, Aragon spun out non-AR (estrogen receptor degrader) program as Seragon Pharmaceuticals.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Johnson & Johnson / Aragon Pharmaceuticals Inc. (this deal) | 2013 | $1.0B | 89 |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $9.0B | 96 |
| Johnson & Johnson / Centocor Inc. | 1999 | $4.9B | 92 |
| Johnson & Johnson / Cougar Biotechnology, Inc. | 2009 | $970M | 91 |
| Johnson & Johnson / Actelion Ltd | 2017 | $30.0B | 90 |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $350M | 83 |
| Johnson & Johnson / Genmab A/S | 2012 | $3.0B | 77 |
← Browse all deals · How we score deals
More: 2013 deals · Johnson & Johnson deals · Oncology deals